75 related articles for article (PubMed ID: 19804184)
1. New therapeutic possibilities for vein graft disease in the post-edifoligide era.
Cai X; Freedman NJ
Future Cardiol; 2006 Jul; 2(4):493-501. PubMed ID: 19804184
[TBL] [Abstract][Full Text] [Related]
2. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.
Conte MS; Lorenz TJ; Bandyk DF; Clowes AW; Moneta GL; Seely BL
Vasc Endovascular Surg; 2005; 39(1):15-23. PubMed ID: 15696244
[TBL] [Abstract][Full Text] [Related]
3. Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass.
Hoel AW; Conte MS
Cardiovasc Drug Rev; 2007; 25(3):221-34. PubMed ID: 17919257
[TBL] [Abstract][Full Text] [Related]
4. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
Ehsan A; Mann MJ; Dell'Acqua G; Dzau VJ
J Thorac Cardiovasc Surg; 2001 Apr; 121(4):714-22. PubMed ID: 11279413
[TBL] [Abstract][Full Text] [Related]
5. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH; Ferguson TB; Joseph DM; Mack MJ; Wolf RK; Gibson CM; Gennevois D; Lorenz TJ; Harrington RA; Peterson ED; Lee KL; Califf RM; Kouchoukos NT;
Am Heart J; 2005 Oct; 150(4):643-9. PubMed ID: 16209958
[TBL] [Abstract][Full Text] [Related]
6. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Mann MJ; Whittemore AD; Donaldson MC; Belkin M; Conte MS; Polak JF; Orav EJ; Ehsan A; Dell'Acqua G; Dzau VJ
Lancet; 1999 Oct; 354(9189):1493-8. PubMed ID: 10551494
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model.
Miyake T; Aoki M; Shiraya S; Tanemoto K; Ogihara T; Kaneda Y; Morishita R
J Mol Cell Cardiol; 2006 Sep; 41(3):431-40. PubMed ID: 16762361
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model.
Miyake T; Aoki M; Morishita R
Cardiovasc Res; 2008 Sep; 79(4):706-14. PubMed ID: 18515844
[TBL] [Abstract][Full Text] [Related]
9. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition.
Yamanouchi D; Banno H; Nakayama M; Sugimoto M; Fujita H; Kobayashi M; Kuwano H; Komori K
J Vasc Surg; 2005 Oct; 42(4):757-64. PubMed ID: 16242565
[TBL] [Abstract][Full Text] [Related]
10. Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts.
Hata JA; Petrofski JA; Schroder JN; Williams ML; Timberlake SH; Pippen A; Corwin MT; Solan AK; Jakoi A; Gehrig TR; Kontos CD; Milano CA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1405-13. PubMed ID: 15942585
[TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts.
Pintucci G; Saunders PC; Gulkarov I; Sharony R; Kadian-Dodov DL; Bohmann K; Baumann FG; Galloway AC; Mignatti P
FASEB J; 2006 Feb; 20(2):398-400. PubMed ID: 16303874
[TBL] [Abstract][Full Text] [Related]
12. Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1.
Wolff RA; Ryomoto M; Stark VE; Malinowski R; Tomas JJ; Stinauer MA; Hullett DA; Hoch JR
J Vasc Surg; 2005 Mar; 41(3):498-508. PubMed ID: 15838486
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor receptor-2 signaling attenuates vein graft neointima formation by promoting endothelial recovery.
Zhang L; Sivashanmugam P; Wu JH; Brian L; Exum ST; Freedman NJ; Peppel K
Arterioscler Thromb Vasc Biol; 2008 Feb; 28(2):284-9. PubMed ID: 18006858
[TBL] [Abstract][Full Text] [Related]
14. [Experimental studies on effect of grafting injury to vein graft].
Yao S; Zhang Y; Tian D
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct; 20(10):1021-5. PubMed ID: 17140079
[TBL] [Abstract][Full Text] [Related]
15. Vascular-wall remodeling of 3 human bypass vessels: organ culture and smooth muscle cell properties.
Mekontso-Dessap A; Kirsch M; Guignambert C; Zadigue P; Adnot S; Loisance D; Eddahibi S
J Thorac Cardiovasc Surg; 2006 Mar; 131(3):651-8. PubMed ID: 16515919
[TBL] [Abstract][Full Text] [Related]
16. Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft.
Handa M; Li W; Morioka K; Takamori A; Yamada N; Ihaya A
J Vasc Surg; 2008 Dec; 48(6):1566-74. PubMed ID: 18848756
[TBL] [Abstract][Full Text] [Related]
17. Transcription factor decoys for the prevention of vein bypass graft failure.
Mann MJ; Conte MS
Am J Cardiovasc Drugs; 2003; 3(2):79-85. PubMed ID: 14727934
[TBL] [Abstract][Full Text] [Related]
18. Towards the treatment of saphenous vein bypass graft failure--a perspective of the Bristol Heart Institute.
Angelini GD; Jeremy JY
Biorheology; 2002; 39(3-4):491-9. PubMed ID: 12122271
[TBL] [Abstract][Full Text] [Related]
19. E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.
Cho WH; Lee SO; Kim HT; Ahn JD; Lee IK
Transplant Proc; 2005; 37(1):77-9. PubMed ID: 15808553
[TBL] [Abstract][Full Text] [Related]
20. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
Ahn JD; Morishita R; Kaneda Y; Kim HS; Chang YC; Lee KU; Park JY; Lee HW; Kim YH; Lee IK
Gene Ther; 2002 Dec; 9(24):1682-92. PubMed ID: 12457282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
